Rakisheva A 1
1. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?
2. Right heart failure with left ventricular assist devices: Preoperative, perioperative and postoperative management strategies. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC
3. Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology
4. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension
5. Reperfusion therapy for ST elevation myocardial infarction in low- to middle-income countries: a clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), the European Association of Percutaneous Cardiovascular Interventions (EAPCI), the European Association of Preventive Cardiology (EAPC), the ESC Working Group on Thrombosis, and the Stent-Save a Life! Initiative
6. Unacceptably high mortality and readmission rates 5 years after heart failure hospitalization: The need to optimize long-term heart failure care by addressing diverse healthcare resources
7. Comparative Analysis of 2 Diagnostic Devices for Detection of Mycobacterium tuberculosis and Drug Resistance in Almaty, Kazakhstan, to Determine the Optimal Diagnostic for Local Needs
8. Rates and risk factors of monoresistance against isoniazid and multidrug-resistant tuberculosis in Almaty, Kazakhstan
9. Awareness, access, and adoption of natriuretic peptides for diagnosis of heart failure
10. Understanding the Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Heart Failure
11. Acute heart failure and valvular heart disease: A scientific statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology
12. Proposing an emancipatory pedagogy of body-mapping in higher education: Theory and practical integration of arts-based research as a form of Action Research for Transformation
13. Genomic Analysis of Multidrug-Resistant Mycobacterium tuberculosis Strains From Patients in Kazakhstan
14. 2025 ESC guidelines for the management of cardiovascular disease and pregnancy, developed by the Task Force on the Management of Cardiovascular Disease and Pregnancy of the European Society of Cardiology (ESC) endorsed by the European Society of Gynecology (ESG)
15. Therapeutic novelties in acute heart failure and practical perspectives
16. 2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations II: diagnostic tests and prediction models
17. Heart failure diagnosis in the general community – Who, how and when? A clinical consensus statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
18. Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart
19. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
20. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology
21. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
22. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
23. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
24. Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology
25. The right heart in patients with cancer. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology
26. Global epidemiology of heart failure
27. Multidrug-Resistant Tuberculosis in Central Asia and Predominant Beijing Lineage, Challenges in Diagnosis, Treatment Barriers, and Infection Control Strategies: An Integrative Review
28. European Society of Cardiology Core Curriculum for cardio-oncology
29. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
30. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
31. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
32. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases : Developed by the task force on the management of peripheral arterial and aortic diseases of the European Society of Cardiology (ESC Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS, the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN, and the European Society of Vascular Medicine (ESVM)
33. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension
34. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
35. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC), with the special contribution of the Heart Failure Association (HFA) of the ESC
36. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC
37. Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC
38. SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI
39. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology
40. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology
41. Education and certification on heart failure of the Heart Failure Association of the European Society of Cardiology
42. Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC)
43. Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology
44. Use of sacubitril/valsartan early after CABG
45. Optimization of renin-angiotensin-aldosterone inhibitor therapies for evidence-based indications: A call to action from the cardio-kidney community
46. Optimization of Renin-Angiotensin-Aldosterone Inhibitor Therapies for Evidence-Based Indications: a Call to Action From the Cardio-Kidney Community
47. Optimization of renin-angiotensin-aldosterone inhibitor therapies for evidence-based indications: a call to action from the cardio-kidney community
48. Epidemiology, detection, diagnosis and treatment of TB in children in Kazakhstan
49. Heart Failure With Preserved Ejection Fraction and Frailty: From Young to Superaged Coexisting HFpEF and Frailty
50. Multidisciplinary care of peripartum heart failure: A scientific statement of the Heart Failure Association of the ESC
1 2